<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">University of Arizona</th>
</tr>
<tr>
<td class="label">Location</td>
<td>Tucson, Arizona, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Public Research University</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.arizona.edu" target="_blank">https://www.arizona.edu</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's Disease, Parkinson's Disease, Neuroimaging, Biomarkers</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1885</td>
</tr>
</table>
The University of Arizona (UArizona), founded in 1885, stands as the state's flagship research university and a prominent national center for neurodegenerative disease research. Located in Tucson, Arizona, the university has grown from its origins as a small territorial school into a world-class research institution serving over 50,000 students across more than 20 colleges and schools. The university's contributions to neuroscience and neurodegeneration research have positioned it as a leader in understanding Alzheimer's disease, Parkinson's disease, and related conditions, with particular strengths in neuroimaging, biomarker development, and clinical trials[@arizon_alzheimers][@uacom].
<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">University of Arizona</th>
</tr>
<tr>
<td class="label">Location</td>
<td>Tucson, Arizona, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Public Research University</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.arizona.edu" target="_blank">https://www.arizona.edu</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's Disease, Parkinson's Disease, Neuroimaging, Biomarkers</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1885</td>
</tr>
</table>
The University of Arizona (UArizona), founded in 1885, stands as the state's flagship research university and a prominent national center for neurodegenerative disease research. Located in Tucson, Arizona, the university has grown from its origins as a small territorial school into a world-class research institution serving over 50,000 students across more than 20 colleges and schools. The university's contributions to neuroscience and neurodegeneration research have positioned it as a leader in understanding Alzheimer's disease, Parkinson's disease, and related conditions, with particular strengths in neuroimaging, biomarker development, and clinical trials[@arizon_alzheimers][@uacom].
The university's location in the southwestern United States provides unique research opportunities, including access to diverse patient populations and collaboration with tribal communities on health disparities research. Arizona's rapidly growing aging population creates urgent need for neurodegenerative disease research, and the university has responded by building comprehensive programs addressing early detection, treatment development, and care optimization for patients with dementia and movement disorders.
With annual research funding exceeding $700 million, the university ranks among the top 20 public research universities in the United States. The College of Medicine, the BIO5 Institute, and affiliated research centers provide infrastructure for interdisciplinary research spanning basic science, translational development, and clinical applications. The Arizona Alzheimer's Consortium coordinates research across multiple institutions, maximizing resources and expertise to accelerate progress against neurodegenerative diseases.
The University of Arizona was established in 1885, just three years after Arizona achieved territorial status, making it one of the oldest public universities in the western United States. The initial focus on agriculture and mining reflected the territory's economic foundations, but the university quickly expanded to encompass broader scientific and medical disciplines. Early medical education was limited, with students typically completing their training at other institutions.
The early 20th century saw gradual expansion of scientific research capabilities, though neurodegenerative disease research had not yet emerged as a distinct field. The university's location in the desert Southwest created unique opportunities for research on environmental health factors, including heat-related conditions and toxic exposures that may influence neurological disease risk.
The College of Medicine was established in 1967, marking a major expansion of the university's health sciences capabilities. Initially focused on primary care training to address Arizona's physician shortage, the medical school gradually developed research capabilities in various specialties. The Barrow Neurological Institute, established in 1960 and later affiliated with the university, became a major center for neurological disease research and treatment.
The late 20th century saw the emergence of neurodegenerative disease research as a priority. The Arizona Alzheimer's and Cognitive Center was established to consolidate research on Alzheimer's disease and related conditions. The Center for Neurobiology of Aging developed programs examining the neuroscience of aging and age-related neurological diseases. These investments positioned the university for leadership in the field as the aging population created growing demand for neurodegenerative disease research.
The past three decades have seen dramatic expansion of neurodegenerative disease research at Arizona. The Arizona Alzheimer's Consortium was established to coordinate research across multiple institutions, including the University of Arizona, Arizona State University, Banner Health, and other partners. This collaborative approach has maximized resources and accelerated progress toward understanding and treating Alzheimer's disease.
The university has become a major participant in national research initiatives, including the Alzheimer's Disease Neuroimaging Initiative (ADNI), the Alzheimer's Disease Clinical Trials Consortium (ACTC), and various National Institute on Aging (NIA)-funded studies[@adni][@actc]. Clinical trials programs have expanded to include numerous pharmaceutical company partnerships testing novel therapeutic approaches.
Research infrastructure has grown substantially, with the BIO5 Institute providing core facilities for genomics, proteomics, imaging, and computational biology[@bio5]. The university has recruited leading researchers in neuroimaging, biomarker development, and therapeutic development, building critical mass in key research areas.
The University of Arizona maintains comprehensive research programs addressing Alzheimer's disease from multiple angles, spanning basic biology, biomarker development, clinical characterization, and therapeutic intervention[@pubmed_alzheimers].
Neuroimaging Research
Arizona researchers have made substantial contributions to neuroimaging in aging and dementia. Studies employing magnetic resonance imaging (MRI) examine structural brain changes including hippocampal atrophy, cortical thinning, and white matter hyperintensities that characterize Alzheimer's disease. Functional MRI studies reveal alterations in brain network connectivity that may provide early markers of cognitive decline.
Positron emission tomography (PET) imaging enables visualization of amyloid plaque pathology in vivo, using radiotracers like Pittsburgh compound B (PiB) and Florbetapir. Tau PET imaging, using tracers like AV-1451 and MK-6240, allows assessment of neurofibrillary tangle burden. The university participates in multi-site studies that standardize imaging protocols across institutions, enabling pooled analysis of neuroimaging data.
Biomarker Development
Arizona researchers contribute to biomarker development for Alzheimer's disease diagnosis and progression monitoring[@pubmed_biomarkers]. Studies examine cerebrospinal fluid biomarkers including amyloid-beta peptides (Aβ42, Aβ40), total tau, and phosphorylated tau (p-tau181, p-tau217). Research also explores blood-based biomarkers that may provide less invasive alternatives to lumbar puncture, including plasma amyloid, tau, and neurofilament light chain measurements.
APOE and Genetics
The university has particular expertise in research on apolipoprotein E (APOE), a major genetic risk factor for Alzheimer's disease[@pubmed_apoe]. Studies examine how different APOE alleles (APOEε2, APOEε3, APOEε4) influence disease risk, age of onset, and pathological features. Research explores mechanisms through which APOE affects amyloid metabolism, neuroinflammation, and neuronal vulnerability.
Research on Parkinson's disease and related movement disorders represents another major focus at Arizona. Investigators study disease mechanisms, develop diagnostic biomarkers, and evaluate therapeutic interventions including pharmacological treatments and surgical approaches[@pubmed_parkinson].
Alpha-Synuclein Research
Arizona researchers investigate alpha-synuclein biology, the protein that accumulates in Lewy bodies characteristic of Parkinson's disease. Studies examine how genetic mutations in the SNCA gene affect protein structure and aggregation. Research explores the cell-to-cell transmission of pathological alpha-synuclein species, a mechanism thought to underlie the progressive spread of pathology.
Deep Brain Stimulation
The Barrow Neurological Institute has particular expertise in deep brain stimulation (DBS) for Parkinson's disease[@barrow]. Studies evaluate optimal stimulation targets (subthalamic nucleus, globus pallidus internus), stimulation parameter optimization, and outcomes in diverse patient populations. Research on adaptive DBS systems explores whether responsiveness to brain activity changes can improve symptom control.
The university has developed expertise in research on neuroinflammation as a contributor to neurodegenerative disease[@pubmed_neuroinflammation]. Studies examine microglial activation patterns, cytokine release, and the contribution of inflammatory processes to neuronal dysfunction. Research explores whether modulating neuroinflammation may provide therapeutic benefits without compromising essential immune functions.
Research on Lewy body dementia represents a significant focus, building on the expertise in alpha-synuclein biology and the clinical programs at Banner-University Medical Center[@pubmed_lewy_body]. Studies examine clinical features distinguishing Lewy body dementia from Alzheimer's disease, including fluctuations in cognition, visual hallucinations, and parkinsonism. Research on biomarkers may improve diagnostic accuracy and enable differentiation from other dementia types.
The Arizona Alzheimer's and Cognitive Center serves as the university's flagship center for dementia research[@arizon_alzheimers]. The center integrates clinical care with research programs, providing comprehensive diagnostic services while generating research data from patient evaluations. Clinical trials programs enable patients to access experimental therapies while contributing to therapeutic development.
The Center for Neurobiology of Aging coordinates research on the neuroscience of aging and age-related neurological diseases. The center brings together investigators from multiple departments, fostering interdisciplinary collaboration. Research programs examine fundamental mechanisms of brain aging and how these processes contribute to neurodegenerative disease.
The Barrow Neurological Institute, affiliated with the university, represents one of the largest neurological disease research centers in the world[@barrow]. The institute provides comprehensive neurological care while maintaining active research programs across multiple conditions. Deep brain stimulation surgery, epilepsy monitoring, stroke treatment, and brain tumor programs complement neurodegenerative disease research.
Banner-University Medical Center serves as the academic medical center affiliated with the university, integrating clinical care with research and education. The memory disorders clinic provides comprehensive evaluation and care for patients with cognitive complaints, including Alzheimer's disease and other dementias. The movement disorders center offers specialized care for Parkinson's disease and related conditions.
The BIO5 Institute provides core research infrastructure supporting neurodegenerative disease research across the university[@bio5]. The institute offers facilities for genomics, proteomics, metabolomics, and computational biology. Bioinformatics resources enable analysis of large-scale datasets generated through research programs.
The College of Medicine provides comprehensive medical training that includes instruction in neurodegenerative diseases. Medical students receive classroom instruction in neuroanatomy, neurophysiology, and clinical neurology. Clinical rotations through neurology and psychiatry provide exposure to patients with Alzheimer's disease, Parkinson's disease, and related conditions.
The residency program in neurology provides extensive training in neurodegenerative diseases, preparing physicians for careers in academic medicine or clinical practice. Fellowship programs in movement disorders and dementia provide specialized training for those pursuing careers as clinician-researchers.
Graduate programs in biomedical sciences include neuroscience tracks that provide training for research careers. PhD programs include coursework in research methods, scientific writing, and professional development. Dissertation research in neuroscience laboratories provides hands-on research experience.
The university offers combined MD/PhD programs for students pursuing careers as physician-scientists. These trainees work alongside established researchers, gaining exposure to cutting-edge approaches to neurodegenerative disease research.
Postdoctoral positions provide advanced training for researchers who have completed their doctoral training. Postdoctoral fellows work in laboratories of established investigators, developing expertise in specific techniques and research areas. Many postdoctoral trainees go on to establish their own research programs at academic institutions worldwide.
The Arizona Alzheimer's Consortium represents a unique collaborative model that brings together researchers from multiple institutions to accelerate progress against Alzheimer's disease and related disorders. The consortium includes:
Arizona's location in the southwestern United States provides unique opportunities for research on health disparities and diverse populations. The university collaborates with tribal communities to study neurodegenerative diseases in populations that have been underrepresented in research.
Studies examine how environmental factors, including altitude, sun exposure, and lifestyle factors, may influence neurodegenerative disease risk. The desert environment creates unique opportunities for research on heat-related health effects and environmental toxicology.
The university's Advanced Imaging Center provides state-of-the-art MRI and PET capabilities for neurodegenerative disease research. The center houses 3T and 7T MRI scanners, PET/CT systems, and cyclotron facilities for producing radiotracers. Researchers can visualize brain structure, function, and pathology in living subjects.
The Arizona Alzheimer's Disease Core Center maintains a biorepository of blood, CSF, and tissue samples from well-characterized research participants. These resources enable researchers to investigate biomarkers and disease mechanisms using diverse molecular approaches.
The data science core provides computational infrastructure for analyzing large datasets, including neuroimaging data, genomic data, and clinical information. Machine learning approaches enable identification of patterns that may predict disease progression or treatment response.
The university is developing precision medicine approaches for neurodegenerative diseases, tailoring diagnostic and therapeutic strategies to individual patient characteristics. Research programs examine genetic risk profiles, biomarker signatures, and clinical phenotypes to predict disease course and treatment response[@reiman2024].
Investigators are developing novel therapeutic approaches for neurodegenerative diseases, including disease-modifying treatments targeting core pathological processes. Research programs examine immunotherapeutic approaches targeting amyloid, tau, and alpha-synuclein[@scheltens2024].
Improving early detection of neurodegenerative diseases remains a priority. Research programs examine whether biomarker panels can identify individuals at risk before symptoms appear[@jack2024].
Dr. Eric Reiman leads Arizona's precision medicine initiative for Alzheimer's disease. His research has characterized brain imaging and biomarker changes in individuals at genetic risk for Alzheimer's, including APOEε4 carriers and carriers of deterministic AD mutations. The Reiman laboratory has developed approaches to enrich clinical trials for individuals most likely to benefit from disease-modifying therapies.
Dr. Casalnuovo has developed novel tau PET imaging approaches that enable visualization of neurofibrillary tangle burden in living patients[@casalnuovo2023]. This research has revealed that tau pathology spreads in a predictable pattern that correlates with clinical symptoms.
Dr. Jagust has made fundamental contributions to understanding the relationship between amyloid plaques and tau pathology in Alzheimer's disease. His work using PET imaging has demonstrated that amyloid influences the spread of tau throughout the brain.
Dr. Scheltens leads clinical trials programs testing novel therapeutic approaches for Alzheimer's disease. His research has contributed to understanding of how to design and execute clinical trials for disease-modifying treatments.
The university participates in numerous clinical trials for Alzheimer's disease: